Kenvue Inc. $KVUE Shares Sold by Korea Investment CORP

Korea Investment CORP trimmed its position in Kenvue Inc. (NYSE:KVUE) by 16.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,054,166 shares of the company’s stock after selling 200,633 shares during the period. Korea Investment CORP owned about 0.05% of Kenvue worth $22,064,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Trust Co. of Vermont raised its position in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the last quarter. Truvestments Capital LLC purchased a new stake in Kenvue in the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after acquiring an additional 1,287 shares during the last quarter. First Pacific Financial purchased a new position in shares of Kenvue during the 2nd quarter worth $54,000. Finally, Ransom Advisory Ltd purchased a new position in shares of Kenvue during the 1st quarter worth $56,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.5%

Shares of NYSE:KVUE opened at $17.31 on Friday. The stock has a 50-day simple moving average of $16.06 and a 200-day simple moving average of $19.56. The stock has a market capitalization of $33.15 billion, a P/E ratio of 23.07 and a beta of 0.71. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same period in the previous year, the company posted $0.28 earnings per share. Kenvue’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s dividend payout ratio is 110.67%.

Analyst Ratings Changes

KVUE has been the subject of several analyst reports. Citigroup dropped their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $22.50 to $22.00 in a report on Friday, September 26th. Barclays raised their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Finally, Jefferies Financial Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.